Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Bonesupport, Audiocast with teleconference, Q2'24

By Inderes7/11/2024, 8:00 AM
Bonesupport

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Emil Billbäck
00:03 - 14:04

Good morning. Thank you. Operator, and welcome everyone to the BONESUPPORT HOLDING AB second quarter 2024 results call. I am Emil Billbäck, the CEO of BONESUPPORT, and I'm making this broadcast as always together with Håkan Johansson, our CFO. We will use the next 25 minutes to guide you through the presentation of the second quarter results, and then we will open up the line for a question and answer session. Before starting the presentation, I would like to draw your attention to the disclaimers that cover any of the forward-looking statements that we might make today. Let's go to slide three. I would like to begin the entire presentation by covering some condensed highlights from the report that we released this morning. Overall, quarter two sales were 220 million SEK, which corresponds to a reported growth of 57% year over year. And in constant exchange rates, the growth rate was 55%. The sales increase was positively influenced by accelerated market penetration of CERAMENT G in the US during the quarter. CERAMENT G in the US reached a milestone of surpassing 100,000 units. We see that the existing customers are continuously increasing their usage, and in addition, new users are constantly being added, resulting in a total growth rate for the company of more than ten times the market rate. We are, of course, taking significant market shares. The strong sales resulted in a record operating result, despite the large investments in R&D that occurred in the quarter before incentive provisions. The operating result was 36 million and our reported EBIT was 29 million SEK. So, as you might have seen from the release of the report this morning, the very strong business momentum has also led us to raise our sales guidance for 2024. Let's move to the highlights of the quarter. Operationally, first of all, I would like to highlight that our new Executive Vice President of Quality Management and Regulatory Affairs, Anette Stark, started about ten days ago. We're very pleased to welcome her and her contribution to our future journey. There has been elevated R&D cost in the quarter. As most of you know, we received US regulatory approval for CERAMENT BVF in interbody fusion in the US in the first quarter of this year; before its launch, which will seemingly take place in quarter four 2025, we will assemble an extensive launch package, including a variety of preclinical application studies, and these studies were started during the quarter and will run into early 2025. Other highlights in the quarter include Cigna's recognition of CMS's transitional pass-through payment, a CMS proposal for a one-year extension of the NTAP, and strong data from Australia on reduced amputation rates with CERAMENT. All these topics will be covered later in the presentation. Let's start by looking at the sales development on slide four. The chart you see shows total last 12 months' sales in Swedish currency every quarter since early 2017, in stacked bars per region and product category. The top line is advancing with a solid and steep trajectory, as CERAMENT rapidly is taking market shares from other treatment options and is even seemingly expanding the market. It is mainly the antibiotic-eluting CERAMENT V which is driving the development, with a total growth of 82% in quarter two of 2024 versus quarter two of 2023. Since the end of the pandemic, where we could again visit customers and promote CERAMENT, we have seen strong progress in both geographic segments with an almost linear development for total sales since early 2022. There are no signs of this trend slowing down. To give you some input on how well CERAMENT is performing in relation to its peers. We have included a slide from one of the most established industry reports. So let's go to that. It's on the next slide. So this is from an institution called, what the world knows as, the leading market intelligence platform within orthopedics. In their recent Orthopedic Annual Report, they summarized the industry's sales performance for 2023. We had to cover the other companies in the matrix to avoid displaying data that does not belong to us, but we left the public companies visible. Well, as you can see in the table, we are still a rather small player in the segment of Orthobiologics, but nevertheless, we are the absolute organic growth leader. As you can see from the numbers we presented today, we have a growth pace of well over 50% for the first six months of 2024. So it is likely that we will move up the list notably for the next annual report. Let's progress in the presentation and go next. Now to North America. Next slide, please. At sales of 173 million SEK in the quarter, this corresponds to a reported growth of 67% year over year and 66% at a constant exchange rate. This means that the US sales in quarter two had a reported sequential growth of 22% over quarter one of 2024. Segment VF grew 13% in the quarter. A lot of new accounts are being generated by the strong interest in CERAMENT G. And some of these new accounts have started to use CERAMENT on patients with very low infection risk. The highlight of the quarter otherwise, of course, was the strong sales of CERAMENT G. In quarter two, we saw very strong uptake and sales reaching 108 million Swedish krona. Surgeons that have pilot use of CERAMENT V at the end of last year have now evaluated patients thoroughly with X-rays and are now ramping up repeat use. At the same time, new surgeons are constantly being added. The surgeons who have done medium-term follow-ups are encouraged that the treatment outcomes are mirroring what has been seen in published clinical studies for CERAMENT. Our transitional path through payment, TPT and the Open Trauma Approval have brought a lot of interest with new surgeons and new clinics for CERAMENT V, but the impact on sales is so far only minor. The big launch conference for the open trauma indication will be the OTA, the Orthopedic Trauma Association meeting from October 20th to 26th, 2024. Now, it is common that some of the private healthcare insurance providers honor the reimbursement issued by Medicare and CMS, the Centers for Medicare and Medicaid Services. The scrutiny and the evaluation by CMS work a bit as a guiding standard. So, the third largest healthcare insurance provider in the US, with more than 20 million people covered, that is. Cigna announced this quarter that they will follow CMS's decision on TPT for the use of CERAMENT G in the outpatient setting. This is an early success on the path towards establishing CERAMENT G as a new standard of care in the US. We will over time report other specific reimbursement schemes by private insurance providers, but we will only do that when it relates to the top providers. And on the slide that is on the screen, you can see the different top providers of private healthcare insurance to the right. The end top. With the evolving success in the US for settlements, including sales, development, market access, reimbursement, and regulatory approvals. We have invested in additional resources to drive further market penetration. We have recruited two clinical specialists to drive segment awareness in the outpatient settings. This is related to the TPT reimbursement. In addition, a senior and well-experienced spine product manager has been hired for the future. Entry into the spine and back office positions were added at the onset of the quarter, in anticipation of increasing demand and the execution of strategic initiatives going forward. The US headcount was 35 at the end of the quarter. The approval and penetration of hospital systems, also known as networks, is progressing well. In the quarter, we have secured several prestigious and high-value hospital system contracts. Now let's turn our attention to Europe and the Rest of the World, which is on the next slide. So much of the focus, of course, in this report has been on the US, given the strong sales development. But I want to underscore that we're seeing excellent progress in Europe, where sentiment is capturing market shares in more or less all markets where we are present. For the quarter, we saw sales of 47 million SEK, corresponding to a reported growth of 28% year over year and 26% at constant exchange rates. We continue to see positive market dynamics as there is a continued catch-up of the surgical backlog in most geographies. There are, however, some sporadic continuing challenges from staff shortages, exacerbated by nurses striking and other disruptions such as the hacker attack on the NHS. The latter might sound trivial, but a disruption of a few days in the surgical theater of major London hospitals is actually visible in surgery volumes. The end of the antibiotic-eluting segment, which combines CERAMENT G and CERAMENT V, is clearly leading the growth trend. The positive differentiation of CERAMENT G and CERAMENT V versus traditional treatment options is well validated in several clinical studies. In the quarter, results from a clinical study conducted in Australia on 136 patients with infected diabetic foot ulcers were published. It was a retrospective study comparing historical patient outcomes with outcomes after switching to CERAMENT G or CERAMENT V. And all of this took place at one specific large clinic. The result displayed an amputation rate of 2% for patients receiving antibiotic-eluting cement, versus the historical rate of 18% when using standard of care. When switching to CERAMENT G or CERAMENT V, the number of patient days in hospital over a 12-month period decreased from 26 to 1 day.

Unknown 1
14:04 - 14:04

To.

Emil Billbäck
14:05 - 14:51

Resolved from 26.1 days to 12.6 days. So it almost cut in half the time that the patients have to stay in the hospital. This is in line with previously published European data. Australia is an attractive market, and in the quarter we changed distributors to ensure that we cover more indications and more hospitals. This study will, of course, be very useful in the hands of our new competent distributor to accelerate market penetration. We have previously concluded, based on solid published evidence, that there are significant health economic benefits to be gained by preventing fracture-related issues.

Unknown 1
14:51 - 14:52

Infections.

Emil Billbäck
14:52 - 16:37

In a well-made Dutch study that was published this quarter. 246 patients with severe fractures were monitored with a mean one-year follow-up. The infection rate within the studied cohort was 18%. The authors concluded that the cost of care tripled for patients who got an infection and required one additional surgical intervention. When this was compared to the patients that were infection-free. The cost was driven by the extra stay in the hospital, the additional procedure, and the use of systemic antibiotics. Now, even worse for those patients who required multiple interventions due to reinfections, the total cost of care rose sevenfold. This speaks in very strong economic favor of CERAMENT G and V, bringing infection rates down to around 4% with a one-stage procedure on severe trauma-induced fractures. Before moving on to the final section. I should mention that we expect to see the principal investigators present the first results from the SOLARIO study at the European Bone and Joint Infection Society meeting on September 26 to 28. And with that, I will hand over to Håkan to guide us on a deep dive into the numbers. Thank you, Emil. So let's move to slide nine. Net sales improved.

Håkan Johansson
16:37 - 21:04

From 140.4 to 219.8 million, equaling a growth of 57%, or 55%, in constant exchange rates. Emil has already spoken about the strong performance in the two segments and the main drivers behind the sales acceleration. So we move forward to slide ten. The contribution from the North America segment improved by 35.1 million and amounted to 66.8 million. The improved contribution results from increased sales, despite the impact of higher costs. Sales and marketing expenses during the quarter amounted to 99 million, compared with 66.5 million in the previous year. Of which, sales commissions and distributor fees amounted to 1.6 million, compared with 36.7 million in the same period last year. From the lower graph showing net sales as bars and gross margin as the orange marker. It can be noted that the gross margin remains very strong, and amounted to 95.8% in Europe and the rest of the world. A contribution of 14.2 million was reported, compared with 7.6 million in the previous year. Sales and marketing expenses increased by 2.1 million and were driven by filling vacancies, an increase in sales representatives, and a high level of market activities to capture the momentum we now see in Europe. From the lower growth in the emerging market, you can see the gross margin remains stable with a minor impact from market mix, featuring a higher ratio of indirect sales in the period. Let's move to the next slide. So, looking at expenses, the increase in selling expenses reflects investments in the organization, as mentioned by Emil. We also invested in systems to improve customer handling, inventory management, and to meet the increasing demand. The sales and marketing expenses for the period also included a $1 million bad debt provision related to the bankruptcy of Steward Health Care System in the US, as presented at our Capital Markets Day in November. R&D is focused on the execution of strategic initiatives such as spinal fusion and a planned marketing authorization submission for CERAMENT B in the US. These initiatives have progressed well during the quarter. We reported an increase in spending and underlying administrative expenses. Excluding the effects from the long-term incentive programs remaining at a stable level, however, impacted by temporary resources and recruitment costs in the quarter. Let's move to the next slide, please. The adjusted profit was reported to be $36 million, compared with $13.6 million for the same period the previous year. This is an improvement of $22.4 million following strong sales performance and despite investments in commercial and innovation efforts. This is the difference between adjusted EBIT and reported EBIT. Our provisions regarding long-term incentive programs amounted to an expense of $7.4 million this period, compared with $7.7 million the previous year. Of the total cost of $7.4 million in the period, $1.4 million was cash flow impacting with a strong momentum in our sales and the revised sales forecast. We have decided to bring forward our plans to further improve our safety stocks of raw materials and semi-finished products. With these adjustments made, we have created a good position for the rest of the year. The increase in inventories, together with the temporary sales growth-driven increase in trade receivables, contributes to a negative cash flow for the period. It is worthwhile mentioning that we had not seen material timing effects in trade receivables with a large inflow of payments in early July. With that, I'll turn the presentation back to Emil.

Emil Billbäck
21:07 - 21:52

Thank you very much, Emil. So, we are, of course, very pleased with the quarterly performance and the continuous solid trend. We're delivering strong sales and solid earnings thanks to the strong market access achieved through agreements with GPOs and IDNs for CERAMENT G, and we have seen a robust sales dynamic over the past 18 months. Given this growth trend and the recent US regulatory approval in open fractures, we are raising our 2024 guidance. We are expecting a sales increase of over 50% in constant currency compared to the previous year. We have strong confidence in the market.

Unknown 1
21:52 - 21:55

Guidance in the long run.

Emil Billbäck
21:55 - 22:31

Sentiment is on track to prove its role as an orthobiologics platform with broad applications in various bone healing indications. We see the two market authorizations earlier this year as the start of this journey. Thanks to its clinical superiority over standard of care, CERAMENT is consistently increasing its user base and enabling surgeons to achieve better patient outcomes. With that, we conclude our presentation and would like to open up the line for questions.

Operator
22:36 - 23:00

If you wish to ask a question, please dial the pound key followed by five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial the pound key followed by six on your telephone keypad. Our next question comes from Christopher Lederberg from Carnegie Investment Bank AB. Please go ahead.

Christopher Lederberg
23:02 - 24:08

Thank you. Good morning. Three questions for me. Firstly, I wonder if you could comment a little bit on how we should think about further investments in selling expenses. Going forward, do you plan to hire additional people in the US organization in the near term? Second question relates to cash flow. Your commentary about, I think, seems to indicate temporarily high receivables, but maybe you could explain how we should think about these issues going forward. Are there any changes there as you add new clients, new indications, etc.? And then finally, this reimbursement recognition by Cigna. How do you think this will impact the sales and demand? And the reason I'm asking is that you have already seen a very strong demand, especially from insurance patients, which seems to have made up a larger portion of sales than what was initially expected. Thank you.

Emil Billbäck
24:11 - 24:25

Thank you, Christopher. So the first question was regarding further investments. The dynamic we see in orthopedics is characterized by very long cycles. So when.

Unknown 1
24:25 - 24:26

Um.

Emil Billbäck
24:26 - 24:50

We received, as we did earlier this year, the TPT-reimbursement in the outpatient setting, we recognized that we should allocate resources to this great opportunity. That's why the hiring has taken place. Another hiring that I mentioned was the Spine Product Manager, who is starting to work towards the introduction.

Unknown 2
24:50 - 24:51

In.

Emil Billbäck
24:51 - 26:05

Quarter four of 2025. So all of these are actually forward-looking investments. They are not costs that come to cope with the existing business. They are investments to further open up new areas like new market segments or new product indications. So when it comes to the US, you should not expect that we will have that kind of hiring going forward. Now it's time for these people to get introduced, to find the structures, and to start contributing to our journey. And then gradually, I think we will also start to see the sales that will come out of these initiatives. So we have different parts of the business. We have plenty of resources working on driving new accounts and taking care of existing accounts. And then we have these strategic investments for the next wave of business development. In terms of penetrating new markets and new indications. When it comes to cash flow, I'll pass over to you, Håkan, to comment on some of the factors that have influenced that in the quarter.

Håkan Johansson
26:05 - 26:54

Thank you, Emil. And I'm so happy to respond. What we see in the second quarter, and what we also try to comment on, is that we see a temporary high. It's always a challenge when you take the temperature of the balance sheet on a specific day, etc. It's not really showing the absolute trends. When we look at the underlying data, we in fact see gradual improvements in the US and Europe, which remain stable. So I think that's something to continue monitoring and look at from a longer time perspective, but it should not be seen as an increase in DSLRs.

Emil Billbäck
26:57 - 28:16

Anything else on that? No. And the final question was on signal. So, what do we expect in terms of impact? We actually see this as very positive. The private insurance providers have already responded very positively to CERAMENT G due to the health economic effect. We can show that there's a reduction in amputations. We can show that there is a reduction in the number of days in hospital and so on. So it felt pretty natural that the third largest private health care insurance provider also adopted a higher reimbursement. It is quite unusual that this happens so quickly. We only received the Cigna TPT-reimbursement in January, so usually such integration with the private insurance companies takes place after one year or 18 months. So, I think this is a testament to the strong documentation we have. So what will be the effect? Well, the effect will be that if there were any doubt in an outpatient setting with a Cigna patient before because

Unknown 1
28:16 - 28:17

the

Emil Billbäck
28:17 - 28:51

DRG reimbursement was low in relation to the ceremony cost, well, that is now most likely eliminated, as the full cost of the ceremony will be covered by Cigna for those procedures. So you could think about a smaller procedure like one on a hand or foot, for a foot surgery which has a low DRG and where the cost otherwise would even exceed the DRG. Well, that potential hurdle is now eliminated by this reimbursement.

Christopher Lederberg
28:52 - 29:05

Could I ask a follow-up on that? So in the inpatient setting. Does all major insurance company follow the NTAP recognized NTAP?

Emil Billbäck
29:07 - 29:36

They do not. We have no notification of any of the private insurance companies that are following the NTAP. Um, but in the inpatient procedures, they are usually much more severe. And they relate to long bones or to more difficult injuries. So the cost is naturally significantly higher. So the same hurdle that I discussed before, Albert mentioned, doesn't occur in the inpatient setting.

Christopher Lederberg
29:37 - 29:38

Okay. That makes sense. Thank you.

Unknown 1
29:39 - 29:40

Thank you.

Operator
29:48 - 29:53

The next question comes from Eric Castle of Danske Bank. Please go ahead.

Unknown 1
29:55 - 29:55

Hi.

Unknown 3
29:55 - 30:07

Good morning everyone. So, just the first question. Can you say anything about the 70 unit volume growth in the US and how that compares to the growth of the number of surgeons using the product?

Emil Billbäck
30:13 - 31:03

Uh, that's a good question. Uh, and you're catching us a little bit off guard because we worked so much on the report, and we actually haven't seen that data yet. Um, what I can share with you is that we have no price erosion. The number of units can vary from month to month and quarter to quarter, depending on if there is a big use of 5 mL, the smaller box for foot and ankle surgeries, or if it's the 10 mL for slightly bigger injuries. But in general, over the last, I would say, 18 months. What you've seen on streaming is that the sales increase is fully reflective of the increase in units. There are small variations back and forth, but the trends are parallel.

Unknown 3
31:03 - 31:18

Uh, I was more getting at if the new user acquisition is outpacing unit growth, or if it's mostly on the growth signal driven by, um, say, surgeons acquired a year ago, let's call it that.

Unknown 1
31:18 - 31:18

Huh?

Emil Billbäck
31:19 - 32:28

Ah, I apologize, I thought you were asking about the specific, uh, the unit growth. So, what you could say, basically, is the very strong growth that we've seen in the launch of CERAMENT G. I had shared at the beginning of the year that it was about 50-50, in terms of the sales growth, 50% coming from existing users and 50% from new users, I would say in quarter two. There is an overweight towards existing users. Of course, as that box, let's say, is significantly growing. We see that a lot of the surgeons that came on board and started using CERAMENT G at the end of last year have now received all the approvals necessary and have started with heavy and extended repetitive use. I think it's also interesting to note that it sometimes takes almost six months for people to land in the full evaluation of CERAMENT with X-rays and everything before really getting into very repetitive use.

Unknown 1
32:31 - 32:31

Mhm.

Unknown 3
32:31 - 33:05

Okay. Thank, you. Makes sense. Um, and then I noticed in the report that you're now seeing that the focus of the sales force is, you know, basically only on introducing new users in Germany. Um, and I know that you've talked about the launch being somewhat stepwise in the US. Uh, but should we see this as some sort of indication that we are now entering a period of not only higher user acquisition, adding more users rather than just educating and helping existing ones? So really long questions, but I'm trying to understand the sort of near-term pace for user acquisition.

Unknown 1
33:05 - 33:06

Yeah, I will try.

Emil Billbäck
33:06 - 34:35

To answer it. Uh, in the beginning of the launch, a big focus was on getting approvals by the IDs and getting the hospital system approvals. This has gone better than anticipated. We are now well over 125 approvals for hospital systems and IDs, with a big focus on the major ones. So, there is a high concentration on the absolutely biggest items in the country. And what happens now is that the salespersons are splitting their time between going to new hospitals that are under these contracts and informing about CERAMENT, and then going back to surgeons who started using CERAMENT maybe 2 or 3, four months ago. Uh, so that's the mix; there will be we will take the pedal off a little bit, the foot off the pedal when it comes to driving. More ID approvals, because we are completely, fully booked in taking care of those hospitals that already belong to IDs, where we have contracts and where many surgeons are calling us and asking to be introduced to CERAMENT. This trend has taken off. Uh, when we got the approval for the indication, open trauma. And as we got the Cigna TPT-reimbursement, that has driven a lot of interest.

Unknown 3
34:39 - 35:00

Okay. Okay. Thank you. Um, and then you talked about the NTAP extension. And I remember I think it was a year ago, you said that the NTAP usage was very low. Basically, no one was using it. I mean, have that changed in a way that the extension matters now, or is it still mostly irrelevant?

Emil Billbäck
35:03 - 36:10

You're correct, Eric. So in the beginning, we saw much less use of NTAP, compared to how large a part of the population is actually connected to Medicare, which is about 17%. That has increased, that has picked up. But at the same time, it's still, it's still our sales with enterprise still below what it would correspond to us as part of the population. And one explanation for that is that enterprise is solely dedicated to inpatient setting where the injury or the damage to the bone is so severe that the DRG is at a very high level. So. The effect of the NTAP is not as big as you would anticipate. The effect of the TPT, which is outpatient where the, the drug is at a lower level.

Unknown 3
36:13 - 36:39

Okay. Thank you. Makes sense. Uh, and then. Sorry, just one last question. I was just going to ask you what can, um. I mean, if the working capital effect is essentially only about timing. I'm just curious about how that happens? Could it relate to, you know, one large system making a significant purchase? Or do you have some kind of unfortunate synchronization of many different systems?

Håkan Johansson
36:41 - 37:12

Yeah, it's not directly linked to a specific system, etc. It's just coincidental if that explanation makes sense. It's about the effect of a specific cutoff day. We have mentioned in the call and in the report that we've seen substantial inflow early in July, which balances what we observe in the balance sheet. And in June.

Emil Billbäck
37:12 - 38:02

You could also look at it that way. We have a large influx of new customers who have started to use the product. They receive the invoice, and before they process it through their system, it takes a bit more effort than with existing customers. So when considering both invoicing and chasing payments, there is a sharp increase at the end of the quarter. Which means that quite a few of them have spilled over into the next quarter. Not with the invoices, but with receiving the payments. So it's a bit of a sudden impact and is very much related to a timing effect. However, it involves many small customers, not just one large one.

Unknown 3
38:03 - 38:09

Okay, perfect. Yeah. It doesn’t seem like anything to worry about too much. Thank you very much, everyone. I'll jump back in as well.

Unknown 1
38:11 - 38:12

Thank you, Eric.

Emil Billbäck
38:13 - 38:14

Have a great summer.

Operator
38:17 - 38:24

The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.

Sten Gustafsson
38:25 - 38:41

Yes. Good morning. I have a question regarding the sales numbers. Were there any unusual orders in Q2, like stocking orders from any customers or anything else that we should be mindful of going forward?

Emil Billbäck
38:43 - 38:59

No, there weren't. The only notable aspect was the unusual amount of many users adopting the system. But no big orders, no stocking orders, and no shelf moving. Every product invoice is a product used on a patient.

Sten Gustafsson
39:00 - 39:37

Great. Thank you. Um, I noticed the uptake in beef sales in the US. Um, it's been, um, relatively flat, um, uh, over several quarters. And now it jumped. Are you sure that there's no sort of pre-usage in the spine of that product? I think you mentioned something during your remarks, which I can't remember now, but it's not spine-driven already now, is it by some early adopters?

Emil Billbäck
39:38 - 41:16

Yeah, I hope not, I hope not, but you never know. Sometimes with these, I mean, they could very well be standard. There is a very experienced user with CERAMENT that comes up with the idea that they also want to use it for spine procedures. It's regulatory approved. But we cannot assist those surgeons with material. We can also not recommend them to do it. What we have seen is that, uh, new customers that have come on board and signed contracts have been initiated on CERAMENT. We have patients with sometimes very low risk of infections where they have been impressed by the bone building capabilities of CERAMENT, but the infection risk is so low that they have used beef instead. And this has meant that a couple of hospitals, where we have had no presence before, have gotten in as suppliers with CERAMENT G. And then there are surgeons that have started to use CERAMENT beef. Um, so one question I received this morning is, is that trend going to continue? Honestly, we don't know because it's just a handful of big hospitals. And I think it's yet to be seen how they evaluate the product and if they want to continue with beef. We hope so. Uh, but I cannot make any, um, guidance for quarter three or quarter four based on what we have seen now.

Sten Gustafsson
41:16 - 41:53

Okay. Fair enough. Um, regarding CERAMENT G, um, which again, was a strong number, and it seems like it has not been driven by the new or the broadening of your approval. Um, um, but should we assume then after the conference, which you said was in like September, that the growth rate will pick up in Q4 even higher than from this broadening of the approval?

Emil Billbäck
41:56 - 42:31

Yeah, it's a very good question. We've seen we've seen a handful of trauma surgeons in level one trauma centers, which are the most heavily frequented and the most prestigious ones that have started to use CERAMENT. But one has to remember that no one will start using CERAMENT for trauma just by reading about the approval. It has to be preceded by training and education from our side. So we can only increase the number of users at the pace of.

Unknown 1
42:31 - 42:31

Our.

Emil Billbäck
42:31 - 43:19

Salespeople being out there informing. So, yes, um, the use and sales of CERAMENT in open trauma is absolutely likely to increase by the end of the year. The big launch conference in October will be our first real opportunity to meet a lot of trauma surgeons in one place and have a generation of influence. Leads and communication on site. Otherwise, it's basically one-to-one that we are meeting in our sales promotion. We also know that adapting techniques and adopting new technologies like this for new indications takes time. So it's something that's going to happen gradually.

Sten Gustafsson
43:21 - 43:46

Very clear. Thank you very much. One final question, if I may, is regarding the R&D costs and how we should think about them in the second half. Is the 20 million level you had in Q2 what we should expect? Will that increase? Gradually now in the second half? Is that what we should expect?

Emil Billbäck
43:48 - 43:50

Do you want to answer that?

Håkan Johansson
43:50 - 44:20

Thanks, Dan. I think what we can say is that the second quarter forms a good reference for the level going forward. Keeping in mind that some of the investments we make and the costs we incur for those initiatives are somewhat volatile in terms of timing, etc. But all in all, I would say that the second quarter remains a good reference.

Sten Gustafsson
44:21 - 44:22

Fantastic. Thankersciom very much.

Emil Billbäck
44:24 - 44:26

Thank you, sir. Have a great summer.

Operator
44:31 - 44:37

The next question comes from Matyas Waddesdon from Carnegie Investment Bank AB. Please go ahead.

Matyas Waddesdon
44:40 - 45:17

Hey, Hamilton. I have two questions. Firstly, to follow up on the previous question here on Simon's DVF. If you could comment and help us understand a little bit about the development of an old customer of yours briefly in the quarter, just to understand the contribution from new accounts. And then also if you could put into perspective what share of hospital systems in the US where DVF is sold compared to the number of hospitals that segment G now addresses. That's the first one.

Unknown 1
45:20 - 45:21

Yes.

Emil Billbäck
45:21 - 46:56

We're not open enough to cut and slice all data, but what I can say is that the growth that you see, the very strong growth you see in quarter two from beef is related to new accounts. The existing accounts also had a good quarter for beef, A bit better than previous quarters. But rather taking it to maybe a few percentage points of growth back and forth. When it comes to segment beef, the number of hospital systems where we have approval is somewhere between 265 and 275. With CERAMENT, it's about 125. So, what if we look at the dynamics here? There are hospital systems where we have received approval for a CERAMENT BVF PDF. But beneath that hospital system, there are hospitals that have not started to use CERAMENT BVF, and with new access, we can present ourselves as offering a full portfolio because these surgeons will also have patients with very low risk of infection. And this is the dynamic that we have seen in quarter two, which has driven these very strong growth rates.

Matyas Waddesdon
46:58 - 47:23

I think that's perfectly clear. Then regarding CERAMENT V, I mean, we certainly hope it can validate many of the findings based on the significant clinical data gathered in the past. But looking at the study here for CERAMENT G and V, what new incremental insights are you hoping this study can reveal?

Emil Billbäck
47:27 - 47:35

Administering systemic antibiotics during surgery has been the standard of care.

Unknown 1
47:36 - 47:36

Many.

Emil Billbäck
47:36 - 48:16

Many years, 50 to 60 years. It's a well-established practice. But there is also the well-established concern of administering four weeks of systemic antibiotics in terms of side effects and the rise of resistant bacteria, which could be the real pandemic we should worry about in the future. For a long time, there have been ways and opportunities to reduce systemic antibiotics.

Unknown 1
48:17 - 48:18

Thus.

Emil Billbäck
48:18 - 49:38

CERAMENT G and V have shown exceptionally good results, but no one has really investigated if CERAMENT G and/or V could reduce the days of systemic antibiotics that patients otherwise have to endure. This study is the first of its kind in that manner. The second point is that the study is conducted on 500 patients under the umbrella network of the European Bone and Joint Infection Society. Thus, the study has a significant impact on moving and shaping the standard of care. The studies that you've seen published recently and that we've discussed today, are great for promoting the product, converting surgeons, and individual hospitals to our side. But CERament V has the potential to effect change on a higher societal, political, and national level. And that's why we're sharing this with you. We have very high expectations and are very excited to see what results will emerge at the end of September.

Matyas Waddesdon
49:40 - 49:43

Alright, I think that's all from me. Thank you very much.

Emil Billbäck
49:45 - 49:50

Thank you, Matthias, and I'll see you next time. Have a great summer. Let's see if we have any further questions.

Operator
49:53 - 49:58

The next question comes from Oskar Bergman from Redeye. Please, go ahead.

Oskar Bergman
50:00 - 50:36

Hello, everyone. And congratulations on the strong sales development. Um, I do have a few questions, and I think that I'm just going to do them one by one, and then you can answer them. So the first one, and we have discussed this before. Uh, you want to hear it again? Um, you have set a new target for 2024 with a 50% sales growth. And that's all nice to hear, but it's not all that significant compared to what we analysts expect already. So why are you not prone to setting financial targets that are a bit longer in terms of time horizon, and perhaps also in terms of profitability?

Emil Billbäck
50:41 - 52:00

Thank you. That's a good wishlist, and I hope we can honor that. Um, I think the reason why we said we just had a one-year guidance is that there is so much movement and so many big changes happening in the market environment in terms of regulatory reimbursements, market penetration. Uh, if we look at the consensus of analysts, um, I'm not disputing what you said, but I would say that most of them expect growth rates for the full year between 40 and 45%. And we can conclude after two quarters that we're at 55%. So we felt that it's prudent to revise our guidance, to share with the market, to inform the analysts that we have such strong confidence in how the demand continues to be strong and keeps picking up. But I hear you loud and clear. And of course, BONESUPPORT will have to come to terms with providing slightly longer guidance, possibly concerning both gross margin and EBIT level. Uh, it's too early for that, but I hear you, and it will come.

Oskar Bergman
52:01 - 52:11

Okay. And, um, I understand the change in working capital and so on, but is there any reason to start worrying about the cash position?

Håkan Johansson
52:13 - 52:35

No, it's not relevant to my question. Oscar, in light of what was reported on the balance sheet today. But trust me, Oscar, it's nothing that keeps me or anyone else sleepless at all. We are confident in the cash flow that we anticipate and the available cash we have.

Emil Billbäck
52:36 - 52:37

Yeah, there's absolutely no risk.

Oskar Bergman
52:38 - 52:57

It's good to hear. Um, and then the R&D expenses going forward. Uh, the Q2 figures, is this something that we will see as sort of a steady state for the coming quarters, or should we expect them to accelerate somewhat?

Håkan Johansson
52:59 - 53:25

Uh, as I responded earlier in the call, Oscar, I believe Q2 to be a good reference point for the next few quarters. Uh, there is always, in the nature of these expenses, a certain underlying volatility in terms of the timing when things occur, etc. but Q2 is a good reference for the next two quarters.

Emil Billbäck
53:26 - 53:59

And I would say, what about after that? So either we will then have strategic projects that we will be very clear in displaying that might replace the ones that are completed, and if not, then R&D will go down again. So you can expect this for the rest of the year. And then there will be a lower level because the increase is now related to the investments in, among other things, preclinical studies on the spine, which we see as a very big initiative.

Oskar Bergman
54:01 - 54:29

Okay. Thanks. And here's my last question. And this is a speculative one. But I mean, so far the clear majority of US sales come from BONESUPPORT actions. But as I understand it, there is still some off-label trauma usage even since the launch. And now with the trauma indication in Q3 and Q4, you expect that in the first year after the launch of trauma, it will surpass the sales that CERAMENT achieved in its first year of launch. BONESUPPORT action.

Unknown 4
54:35 - 54:35

Huh?

Emil Billbäck
54:35 - 55:21

Okay, uh, I think we have to come back to that question. I will do my best to answer it, but, um. The open trauma is clearly, uh, a bigger indication. It's, uh, an indication also where it makes, um, significant health and economic sense to use CERAMENT. I think we've seen in some recent publications what really could happen if the infection is not prevented: up to a sevenfold, threefold cost increase? But you're asking more about the pace of ramp-up. And I will just need more observations before I can give any hint on that. So I'll remain as curious as you all are.

Oskar Bergman
55:22 - 55:23

Okay, I'll come back in Q1.

Emil Billbäck
55:23 - 55:28

Maybe you are most welcome. And until then, have a great summer.

Unknown 1
55:29 - 55:29

Thank for your attention.

Oskar Bergman
55:29 - 55:29

You too.

Operator
55:34 - 55:40

The next question comes from Christopher Lederberg from Carnegie Investment Bank AB. Please go ahead.

Unknown 1
55:50 - 55:51

Let's see.

Operator
55:53 - 55:59

Christopher Lederberg, your line is now unmuted. Please go ahead.

Christopher Lederberg
56:00 - 56:31

Yeah. Thank you. Uh, two follow-ups. Uh, first, can you comment on the administrative approvals among hospitals for the trauma indication, how that is going ahead of the launch? And then I just wonder, also on the other sales line, um, that were up quite a bit sequentially in the US, whether there is something specific in the quarter, or if this is also reflecting a new trend for those products.

Unknown 1
56:33 - 56:36

Yeah. The, um.

Emil Billbäck
56:37 - 58:52

The addition of information in the systems where we have approval already, where we have contracts, uh, for bone infection and we're adding, uh, open trauma has gone very well. I mentioned before that we will be completely through by the 1st of September. I think it's likely that it happens now by mid-August. We see great progression and, given that we have both in one hand, we have received FDA market authorization. On the other hand, we have conducted clinical studies and obtained health economic data. It's progressing slightly better than we thought, easier than we anticipated. It was more difficult to address the bone infection initially than it was to add open trauma to the approval. The second point concerns the ancillary products, which are the support products or the specific tools and hardware for injection in the reconstructive plastic area, just above or below a joint. It's also a type of plastic tube that we use so that cement can be accurately placed and filled into targeted areas. Our products allow for non-invasive or minimally invasive procedures that enable us to reach difficult places. There are also application support tools like a bead tray to create small pellets of cement. Specifically, if there's a wound with significant exudate or drainage, the use of our cement is increasing because it is being used in wider and broader indications. This increase can also signify growing use in trauma and open fractures where some of these tools are specifically used.

Christopher Lederberg
58:55 - 58:57

Okay. Great. Thank you.

Unknown 1
58:58 - 58:59

Thank you.

Emil Billbäck
59:03 - 59:28

Additionally, addressing Christopher's point, I realized I missed part of his question earlier concerning whether this trend will continue? Yes. These numbers can fluctuate by a few million back and forth. But over time, we anticipate seeing an ongoing increase as cement is employed in various applications and techniques.

Operator
59:35 - 59:43

There are no more submitted questions at this time, so I will hand the conference back to the speakers for any written questions or closing comments.

Emil Billbäck
59:47 - 60:11

Yes, thank you. We've used a full hour for this conference. Thank you, everyone, for your insightful questions and your interest in BONESUPPORT. We are delighted to have delivered a great quarter and wish all of you a fantastic summer. We look forward to staying in touch and seeing you soon. We approach the fall with great enthusiasm. Thank you everyone, and take care.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…